BRWA
ALNY icon

B. Riley Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

B. Riley Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,575
Closed -$268K – 1382
2021
Q4 		$268K Buy
+1,575
New +$293K 0.01% 1129
2015
Q1 		– Sell
-10
Closed -$1K – 627
2014
Q4 		$1K Buy
+10
New +$926 ﹤0.01% 3514

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

B. Riley Wealth Advisors's ALNY Position: Q1 2022 in Review

B. Riley Wealth Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 1,575 shares — an estimated $268K sold.

B. Riley Wealth Advisors first reported a position in ALNY in Q4 2014 and held it in 2 quarters. The position peaked at $268K in Q4 2021. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • B. Riley Wealth Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 1,575 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $268K.
  • B. Riley Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • B. Riley Wealth Advisors's Alnylam Pharmaceuticals position peaked at $268K in Q4 2021.
  • 444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2022, filed 2 May 2022.